The Safety and Antibody Response of the Nasal COV2 Vaccine Against the SARS-CoV-2 Virus

Launched by ROKOTE LABORATORIES FINLAND OY · Feb 24, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new nasal vaccine called COV2, which aims to protect against COVID-19 by helping the body develop an immune response to the virus. Researchers want to find out how safe this vaccine is and how well it works at different doses and when given as nasal drops or a nasal spray. The trial will include participants who have either received at least two doses of any COVID-19 vaccine or have never been vaccinated against COVID-19 before.

To be eligible for the trial, participants must be between 18 and 75 years old and in good general health. They should not be pregnant, planning to become pregnant, or breastfeeding, and they should not have had a COVID-19 infection in the last nine months or any other vaccinations in the last two months. If someone decides to join the study, they can expect to receive either the low or high dose of the vaccine through one of the two delivery methods. This trial is currently recruiting participants, and it's a great opportunity for those looking to contribute to the fight against COVID-19 while helping researchers learn more about this potential vaccine.

Gender

ALL

Eligibility criteria

• • Inclusion Criteria
• • 1. Has voluntarily signed the written informed consent
• • 2. 18-75 years old
• • 3. Good general health
• • 4. a) Prior vaccination with at least two doses of any COVID-19 vaccine, OR b) No prior COVID-19 vaccination
• • Exclusion Criteria
• • 1. Pregnant, planning to become pregnant or breastfeeding women
• • 2. COVID-19 infection within the last nine (9) months
• • 3. Any other vaccination within the last two (2) months